244 related articles for article (PubMed ID: 36815984)
1. Breviscapine alleviates podocyte injury by inhibiting NF-κB/NLRP3-mediated pyroptosis in diabetic nephropathy.
Sun L; Ding M; Chen F; Zhu D; Xie X
PeerJ; 2023; 11():e14826. PubMed ID: 36815984
[TBL] [Abstract][Full Text] [Related]
2. Astragaloside IV Attenuates High-Glucose-Induced Impairment in Diabetic Nephropathy by Increasing Klotho Expression via the NF-
He J; Cui J; Shi Y; Wang T; Xin J; Li Y; Shan X; Zhu Z; Gao Y
J Diabetes Res; 2023; 2023():7423661. PubMed ID: 37261217
[TBL] [Abstract][Full Text] [Related]
3. TRIM29 promotes podocyte pyroptosis in diabetic nephropathy through the NF-kB/NLRP3 inflammasome pathway.
Xu X; Qin Z; Zhang C; Mi X; Zhang C; Zhou F; Wang J; Zhang L; Hua F
Cell Biol Int; 2023 Jun; 47(6):1126-1135. PubMed ID: 36841942
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of NLRP3 inflammasome ameliorates podocyte damage by suppressing lipid accumulation in diabetic nephropathy.
Wu M; Yang Z; Zhang C; Shi Y; Han W; Song S; Mu L; Du C; Shi Y
Metabolism; 2021 May; 118():154748. PubMed ID: 33675822
[TBL] [Abstract][Full Text] [Related]
5. Triptolide protects against podocyte injury in diabetic nephropathy by activating the Nrf2/HO-1 pathway and inhibiting the NLRP3 inflammasome pathway.
Lv C; Cheng T; Zhang B; Sun K; Lu K
Ren Fail; 2023 Dec; 45(1):2165103. PubMed ID: 36938748
[No Abstract] [Full Text] [Related]
6. Lysophosphatidic Acid Induces Podocyte Pyroptosis in Diabetic Nephropathy by an Increase of Egr1 Expression via Downregulation of EzH2.
Kim D; Ban KY; Lee GH; Jun HS
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373116
[TBL] [Abstract][Full Text] [Related]
7. FOXM1-activated SIRT4 inhibits NF-κB signaling and NLRP3 inflammasome to alleviate kidney injury and podocyte pyroptosis in diabetic nephropathy.
Xu X; Zhang L; Hua F; Zhang C; Zhang C; Mi X; Qin N; Wang J; Zhu A; Qin Z; Zhou F
Exp Cell Res; 2021 Nov; 408(2):112863. PubMed ID: 34626587
[TBL] [Abstract][Full Text] [Related]
8. ManNAc protects against podocyte pyroptosis via inhibiting mitochondrial damage and ROS/NLRP3 signaling pathway in diabetic kidney injury model.
Gao Y; Ma Y; Xie D; Jiang H
Int Immunopharmacol; 2022 Jun; 107():108711. PubMed ID: 35338958
[TBL] [Abstract][Full Text] [Related]
9. STING deletion alleviates podocyte injury through suppressing inflammation by targeting NLRP3 in diabetic kidney disease.
Yang X; Chen Z; Luo Z; Yang D; Hao Y; Hu J; Feng J; Zhu Z; Luo Q; Zhang Z; Liang W; Ding G
Cell Signal; 2023 Sep; 109():110777. PubMed ID: 37329999
[TBL] [Abstract][Full Text] [Related]
10. Artificially Cultivated
Wang C; Hou XX; Rui HL; Li LJ; Zhao J; Yang M; Sun LJ; Dong HR; Cheng H; Chen YP
J Diabetes Res; 2018; 2018():1390418. PubMed ID: 30534570
[TBL] [Abstract][Full Text] [Related]
11. Solasonine alleviates high glucose-induced podocyte injury through increasing Nrf2-medicated inhibition of NLRP3 activation.
Zhang Q; Hu Y; Hu JE; Zhang M
Drug Dev Res; 2022 Nov; 83(7):1697-1706. PubMed ID: 36048966
[TBL] [Abstract][Full Text] [Related]
12. Berberine ameliorates diabetic nephropathy by inhibiting TLR4/NF-κB pathway.
Zhu L; Han J; Yuan R; Xue L; Pang W
Biol Res; 2018 Mar; 51(1):9. PubMed ID: 29604956
[TBL] [Abstract][Full Text] [Related]
13. Penehyclidine hydrochloride suppresses inflammation response and reduces podocyte injury in diabetic nephropathy by targeting fibrinogen-like protein 2.
Tan HB; Zhao Q; Chen L
Int Immunopharmacol; 2022 Jun; 107():108680. PubMed ID: 35303505
[TBL] [Abstract][Full Text] [Related]
14. Spop ameliorates diabetic nephropathy through restraining NLRP3 inflammasome.
Wang B; Dai Z; Gao Q; Liu Y; Gu G; Zheng H
Biochem Biophys Res Commun; 2022 Feb; 594():131-138. PubMed ID: 35081502
[TBL] [Abstract][Full Text] [Related]
15. Sarsasapogenin alleviates diabetic nephropathy through suppression of chronic inflammation by down-regulating PAR-1: In vivo and in vitro study.
Tang ZZ; Zhang YM; Zheng T; Huang TT; Ma TF; Liu YW
Phytomedicine; 2020 Nov; 78():153314. PubMed ID: 32882582
[TBL] [Abstract][Full Text] [Related]
16. Protective effect of ginsenoside metabolite compound K against diabetic nephropathy by inhibiting NLRP3 inflammasome activation and NF-κB/p38 signaling pathway in high-fat diet/streptozotocin-induced diabetic mice.
Song W; Wei L; Du Y; Wang Y; Jiang S
Int Immunopharmacol; 2018 Oct; 63():227-238. PubMed ID: 30107367
[TBL] [Abstract][Full Text] [Related]
17. Pyrroloquinoline quinone ameliorates renal fibrosis in diabetic nephropathy by inhibiting the pyroptosis pathway in C57BL/6 mice and human kidney 2 cells.
Qu X; Zhai B; Liu Y; Chen Y; Xie Z; Wang Q; Wu Y; Liu Z; Chen J; Mei S; Wu J; You Z; Yu Y; Wang Y
Biomed Pharmacother; 2022 Jun; 150():112998. PubMed ID: 35489281
[TBL] [Abstract][Full Text] [Related]
18. Study on the inhibitive effect of Catalpol on diabetic nephropathy.
Chen J; Yang Y; Lv Z; Shu A; Du Q; Wang W; Chen Y; Xu H
Life Sci; 2020 Sep; 257():118120. PubMed ID: 32693244
[TBL] [Abstract][Full Text] [Related]
19. Adiponectin protects obesity-related glomerulopathy by inhibiting ROS/NF-κB/NLRP3 inflammation pathway.
Xu X; Huang X; Zhang L; Huang X; Qin Z; Hua F
BMC Nephrol; 2021 Jun; 22(1):218. PubMed ID: 34107901
[TBL] [Abstract][Full Text] [Related]
20. Caspase-11/4 and gasdermin D-mediated pyroptosis contributes to podocyte injury in mouse diabetic nephropathy.
Cheng Q; Pan J; Zhou ZL; Yin F; Xie HY; Chen PP; Li JY; Zheng PQ; Zhou L; Zhang W; Liu J; Lu LM
Acta Pharmacol Sin; 2021 Jun; 42(6):954-963. PubMed ID: 32968210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
